FDMT FY 2019 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-50.6% YoY

Gross Profit

-$32M-454.2% margin

Operating Income

-$51M-726.7% margin

Net Income

-$49M-705.8% margin

EPS (Diluted)

$-2.00

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$40M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$58M

Total Liabilities

$131M

Stockholders' Equity

-$73M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$14M	-50.6%
Gross Profit	-$32M	-$4M	-649.8%
Operating Income	-$51M	-$10M	-388.2%
Net Income	-$49M	-$10M	-416.2%